175 related articles for article (PubMed ID: 35321601)
21. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
Montemurro F; Di Cosimo S; Arpino G
Ann Oncol; 2013 Nov; 24(11):2715-24. PubMed ID: 23908178
[TBL] [Abstract][Full Text] [Related]
22. Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer.
Dolatkhah M; Hashemzadeh N; Barar J; Adibkia K; Aghanejad A; Barzegar-Jalali M; Omidi Y
Colloids Surf B Biointerfaces; 2020 Sep; 193():111104. PubMed ID: 32417466
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicine applications in the treatment of breast cancer: current state of the art.
Wu D; Si M; Xue HY; Wong HL
Int J Nanomedicine; 2017; 12():5879-5892. PubMed ID: 28860754
[TBL] [Abstract][Full Text] [Related]
24. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
25. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
26. An immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer.
Ramírez-García G; Panikar SS; López-Luke T; Piazza V; Honorato-Colin MA; Camacho-Villegas T; Hernández-Gutiérrez R; De la Rosa E
Nanoscale; 2018 May; 10(21):10154-10165. PubMed ID: 29785440
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
28. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
29. HER2-positive breast cancer, how far away from the cure?-on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients.
Liao N
Chin Clin Oncol; 2016 Jun; 5(3):41. PubMed ID: 27265303
[TBL] [Abstract][Full Text] [Related]
30. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
31. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
32. HER2-targeted therapies in gastric cancer.
Zhu Y; Zhu X; Wei X; Tang C; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188549. PubMed ID: 33894300
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
34. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
Hao Y; Meyer N; Song X; Shi N; Johnson W; Juneau P; Yardley DA; Willemann Rogerio J
Curr Med Res Opin; 2015 Feb; 31(2):275-88. PubMed ID: 25365467
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
39. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
40. Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer.
Gombos A; Franzoi MA; Awada A
Expert Opin Investig Drugs; 2019 Jul; 28(7):617-627. PubMed ID: 31230485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
